MCID: DCT002
MIFTS: 54

Ductal Carcinoma in Situ malady

Category: Cancer diseases

Aliases & Classifications for Ductal Carcinoma in Situ

About this section

Aliases & Descriptions for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ 10 12 24
 
Noninfiltrating Intraductal Carcinoma 65

Classifications:



External Ids:

Disease Ontology10 DOID:0060074
UMLS65 C0007124

Summaries for Ductal Carcinoma in Situ

About this section
Wikipedia:68 Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

MalaCards based summary: Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to breast disease and comedo carcinoma. An important gene associated with Ductal Carcinoma in Situ is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways are Central carbon metabolism in cancer and Transcription Ligand-dependent activation of the ESR1/SP pathway. Affiliated tissues include breast, lymph node and prostate, and related mouse phenotypes are craniofacial and pigmentation.

Related Diseases for Ductal Carcinoma in Situ

About this section

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 277)
idRelated DiseaseScoreTop Affiliating Genes
1breast disease30.8EGFR, ESR1, TP53
2comedo carcinoma30.4EGFR, KRT14, TP53
3papillary carcinoma30.3CDH1, ERBB2, MUC1, PGR
4breast cancer24.5AR, BRCA1, BRCA2, CCND1, CDH1, CLDN7
5flat ductal epithelial atypia10.9EGFR, ERBB2
6congenital pulmonary veins atresia or stenosis10.9BRCA1, BRCA2
7lymphatic system disease10.8EGFR, TP53
8hypogonadotropic hypogonadism-frontoparietal alopecia syndrome10.8EGFR, TP53
9bronchiolitis obliterans10.8BRCA1, BRCA2
10metachronous kidney wilms' tumor10.8PGR, TP53
11congenital disorder of glycosylation, type if10.8ERBB2, TP53
12pituitary gland disease10.8ERBB2, ESR1
13breast cancer, childhood10.7BRCA1, BRCA2
14brca2 hereditary breast and ovarian cancer syndrome10.7BRCA1, BRCA2
15spindle cell carcinoma10.7CDH1, TP53
16pancreatic cancer 410.7BRCA1, BRCA2
17ovarian mucinous cystadenofibroma10.7PTGS2, TP53
18autoimmune polyendocrine syndrome type 110.7BRCA1, BRCA2, ERBB2
19syringoma10.7ESR1, PGR
20microglandular adenosis10.7CCND1, ERBB2, TP53
21endocrine organ benign neoplasm10.7ESR1, PGR
22cervical benign neoplasm10.7ESR1, PGR
23adenofibroma10.7EGFR, ERBB2, PGR
24large bowel leiomyoma10.7ESR1, PGR
25her2-receptor positive breast cancer10.7EGFR, ERBB2, PGR
26bile duct cystadenoma10.7ESR1, PGR
27adult central nervous system mixed germ cell tumor10.6ERBB2, PTGS2, TP53
28cribriform carcinoma10.6ERBB2, ESR1
29breast ductal carcinoma10.6
30tetrasomy 2110.6BRCA1, BRCA2, TP53
31venous tributary occlusion of retina10.6ESR1, PGR
32autoimmune disease of urogenital tract10.6BRCA1, BRCA2, PGR
33malignant testicular leydig cell tumor10.6BRCA1, BRCA2, PGR
34spondyloepimetaphyseal dysplasia, sponastrime type10.6BRCA1, BRCA2, TP53
35ovary neuroendocrine neoplasm10.6PGR, TP53
36glaucoma iridogoniodysgenesia10.6ERBB2, ESR1, PGR
37ulnar neuropathy10.6CCND1, PTGS2, TP53
38spinal cord astrocytoma10.6CDKN2A, TP53
39vulvar squamous papilloma10.6ESR1, PGR
40apocrine adenosis of breast10.6ERBB2, ESR1, PGR
41intramuscular hemangioma10.5MUC1, PGR
42uterine corpus adenosarcoma10.5ESR1, PGR, TP53
43epidermal nevus vitamin d resistant rickets10.5EGFR, ERBB2, MUC1
44pancreatic serous cystadenocarcinoma10.5BRCA1, BRCA2, ERBB2, TP53
45endometrial mucinous adenocarcinoma10.5BRCA1, BRCA2, ERBB2, TP53
46bleeding disorder, platelet-type, 1310.5BRCA2, CYP19A1, TP53
47corneal neovascularization10.5CDH1, PGR, TP53
48male reproductive organ benign neoplasm10.5ESR1, PGR, TP53
49pyelonephritis10.5CDH1, PGR, TP53
50signet ring basal cell carcinoma10.5KRT5, TP53

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to ductal carcinoma in situ

Symptoms for Ductal Carcinoma in Situ

About this section

Drugs & Therapeutics for Ductal Carcinoma in Situ

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Nolvadex15 41 TAMOXIFEN CITRATE AstraZeneca October 1998
FDA Label: Nolvadex
Disease/s that Drug Treats:Breast Cancer
Indications and Usage:15 Metastatic Breast Cancer:NOLVADEX is effective in the treatment of metastatic breast cancer in women and men. Inpremenopausal women with metastatic breast cancer, NOLVADEX is an alternative tooophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumorsare estrogen receptor positive are more likely to benefit from NOLVADEX therapy.Adjuvant Treatment of Breast Cancer:NOLVADEX is indicated for the treatment of node-positive breast cancer in women followingtotal mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In someNOLVADEX adjuvant studies, most of the benefit to date has been in the subgroup with four ormore positive axillary nodes.NOLVADEX is indicated for the treatment of axillary node-negative breast cancer in womenfollowing total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.The estrogen and progesterone receptor values may help to predict whether adjuvantNOLVADEX therapy is likely to be beneficial.NOLVADEX reduces the occurrence of contralateral breast cancer in patients receiving adjuvantNOLVADEX therapy for breast cancer.Ductal Carcinoma in Situ (DCIS):In women with DCIS, following breast surgery and radiation, NOLVADEX is indicated toreduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of thelabel). The decision regarding therapy with NOLVADEX for the reduction in breast cancerincidence should be based upon an individual assessment of the benefits and risks ofNOLVADEX therapy.Current data from clinical trials support five years of adjuvant NOLVADEX therapy for patientswith breast cancer. Reduction in Breast Cancer Incidence in High Risk Women:NOLVADEX is indicated to reduce the incidence of breast cancer in women at high risk forbreast cancer. This effect was shown in a study of 5 years planned duration with a medianfollow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. Thelonger-term effects are not known. In this study, there was no impact of tamoxifen on overall orbreast cancer-related mortality (see BOXED WARNING at the beginning of the label).NOLVADEX is indicated only for high-risk women. “High risk” is defined as women at least35 years of age with a 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the GailModel.Examples of combinations of factors predicting a 5-year risk ≥ 1.67% are:Age 35 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, and ahistory of a breast biopsy showing atypical hyperplasia; or At least 2 first degree relatives with a history of breast cancer, and a personal history of atleast one breast biopsy; or LCISAge 40 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at firstlive birth 25 or older, and age at menarche 11 or younger; or At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 oryounger; or One first degree relative with a history of breast cancer, and a personal history of a breastbiopsy showing atypical hyperplasia.Age 45 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 oryounger; or One first degree relative with a history of breast cancer with a personal history of a benignbreast biopsy, age at menarche 11 or less and age at first live birth 20 or more.Age 50 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer; or History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 orolder and age at menarche 11 or less; or History of at least two breast biopsies with a history of atypical hyperplasia, and age at firstlive birth 30 or more.Age 55 or older and any of the following combination of factors: One first degree relative with a history of breast cancer with a personal history of a benignbreast biopsy, and age at menarche 11 or less; or History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first livebirth 20 or older.Age 60 or older and: 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model.For women whose risk factors are not described in the above examples, the Gail Model isnecessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a GailModel Risk Assessment Tool by dialing 1-800-544-2007.There are insufficient data available regarding the effect of NOLVADEX on breast cancerincidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specificrecommendations on the effectiveness of NOLVADEX in these patients.After an assessment of the risk of developing breast cancer, the decision regarding therapy withNOLVADEX for the reduction in breast cancer incidence should be based upon an individualassessment of the benefits and risks of NOLVADEX therapy. In the NSABP P-1 trial,NOLVADEX treatment lowered the risk of developing breast cancer during the follow-up periodof the trial, but did not eliminate breast cancer risk (See Table 3 in CLINICALPHARMACOLOGY).
DrugBank Targets:13 1. Estrogen receptor;2. Estrogen receptor beta;3. 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;4. Protein kinase C
Mechanism of Action:15 
Target: estrogen receptors
Action: competitor with estraidiol
FDA: NOLVADEX is a nonsteroidal agent that has demonstrated potent antiestrogenic properties inanimal test systems. The antiestrogenic effects may be related to its ability to compete withestrogen for binding sites in target tissues such as breast. Tamoxifen inhibits the induction of ratmammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression ofalready established DMBA-induced tumors. In this rat model, tamoxifen appears to exert itsantitumor effects by binding the estrogen receptors.In cytosols derived from human breast adenocarcinomas, tamoxifen competes with estradiol forestrogen receptor protein.

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 186)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FluorouracilapprovedPhase 3168451-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
2
EpirubicinapprovedPhase 3, Phase 236156420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
3
Cyclophosphamideapproved, investigationalPhase 3, Phase 2264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
4
TamoxifenapprovedPhase 3, Phase 2, Phase 135010540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Soltamox
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
5
MethotrexateapprovedPhase 314441959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
Methopterin
Methotextrate
 
Methotrate
Methotrexat
Methotrexate
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metoject
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Otrexup
Rasuvo
Rheumatrex
Rheumatrex Dose Pack
Trexall
6
Anastrozoleapproved, investigationalPhase 3, Phase 2262120511-73-12187
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
AC-4234
AC1L1D49
Anastrazole
Anastrole
Anastrozol
Anastrozole
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
C08159
C090450
C17H19N5
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
 
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD-1033
ZD1033
ZINC00000941
Zeneca ZD 1033
Zeneca brand of anastrozole
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
anastrozole
7
PertuzumabapprovedPhase 3, Phase 2109145040-37-5, 380610-27-52540
Synonyms:
2C4 Antibody
380610-27-5
D05446
Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
LS-185920
MOAB 2C4
MOAB2C4
Monoclonal Antibody 2C4
 
Omnitarg
Perjeta
Pertuzumab
Pertuzumab (USAN/INN)
Pertuzumab (genetical recombination)
Pertuzumab (genetical recombination) (JAN)
pertuzumab
rhuMAb 2C4
rhuMAb-2C4
8
ProgesteroneapprovedPhase 3, Phase 2, Phase 050057-83-05994
Synonyms:
(S)-4-Pregnene-3,20-dione
(S)-Pregn-4-en-3,20-dione
(S)-Progesterone
.beta.-Progesterone
.delta.(sup4)-Pregnene-3,20-dione
.delta.4-Pregnene-3,20-dione
17.alpha.-Progesterone
17a-Progesterone
17alpha-Progesterone
17alpha-progesterone
17α-progesterone
1dbb
1h60
257630-50-5
3,20-Pregnene-4
32104FB6-BF81-4F6E-83C2-024DEEAEB272
4-Pregnen-3,20-dione
4-Pregnene-3,20-dione
46665_FLUKA
46665_RIEDEL
57-83-0
753497-20-0
8012-32-6
8023-13-0
AC-700
AC1L1LKF
AI3-51682
Agolutin
Akrolutin
BB_NC-0185
BHR-100
BIDD:ER0547
BIDD:PXR0094
BPBio1_000676
BRD-K64994968-001-03-6
BSPBio_000614
Bio-luton
C00410
CCRIS 533
CHEBI:17026
CHEMBL103
CID5994
CIDR
CMC_13406
COL-1620
CPD000058345
Colprosterone
Corlutin
Corlutina
Corluvite
Corporin
Corpus Luteum Hormone
Corpus luteum hormone
Crinone
Crinone (TN)
Crinone progesterone gel
Curretab
Cyclogest
Cyclogesterin
D00066
D4-Pregnene-3,20-dione
DB00396
DR-2011
Delalutin
Delta(4)-pregnene-3,20-dione
Duraprogen
EINECS 200-350-6
ETI-411
EU-0100895
Endometrin
Estima
FE-999913
Flavolutan
Fologenon
Gelbkoerperhormon
Gesterol
Gesterol 100
Gesterol 50
Gestiron
Gestone
Gestormone
Gestron
Glanducorpin
Gynlutin
Gynoluton
Gynolutone
HMS1569O16
HMS2051O05
HMS2090J07
HSDB 3389
Hormoflaveine
Hormoluton
Hydroxyprogesterone Caproate
Hydroxyprogesterone Caproic acid
LMST02030159
LS-234
Lingusorbs
Lipo-Lutin
Lipolutin
Lopac0_000895
Lucorteum
Lucorteum Sol
Lucorteum sol
Lugesteron
Luteal hormone
Luteinique
Luteocrin normale
Luteodyn
Luteogan
Luteohormone
Luteol
Luteol (VAN)
Luteopur
Luteosan
Luteostab
Luteovis
Luteum
Lutex
Lutidon
Lutin
Lutinus
Lutociclina
Lutocuclin M
Lutocyclin
Lutocyclin M
 
Lutocyclin m
Lutocylin
Lutocylol
Lutoform
Lutogyl
Lutogynon
Lutren
Lutromone
MLS000028517
MLS000758277
MLS001074187
MLS002222367
MPA
Membrettes
Methylpregnone
Micronized Progesterone
MolPort-001-794-643
NCGC00022185-03
NCGC00022185-04
NCGC00022185-05
NCGC00022185-06
NCGC00022185-07
NCGC00022185-08
NCGC00022185-09
NCGC00090798-01
NCGC00090798-02
NCI60_042166
NSC 64377
NSC 9704
NSC-9704
NSC64377
NSC9704
Nalutron
Natural Progesterone
P 0130
P0130_SIGMA
P0478
P3972_SIGMA
P6149_SIGMA
P7556_ALDRICH
P7556_SIGMA
P8783_SIGMA
P9776_SIGMA
PROGESTERONE
Percutacrine
Percutacrine Luteinique
Piaponon
Pranone
Pregn-4-en-3,20-dione
Pregn-4-ene-3,20-dione
Pregnene-3,20-dione
Pregnenedione
Prestwick0_000477
Prestwick1_000477
Prestwick2_000477
Prestwick3_000477
Prestwick_411
Primolut
Prochieve
Progeffik
Progekan
Progestan
Progestasert
Progesterol
Progesteron
Progesterona
Progesterona [INN-Spanish]
Progesterone
Progesterone (JP15/USP/INN)
Progesterone [INN:BAN:JAN]
Progesterone [Progestins]
Progesterone, water-soluble
Progesterone-Water Soluble
Progesterone: HBC complex
Progesteronum
Progesteronum [INN-Latin]
Progestin
Progestogel
Progestol
Progeston
Progestone
Progestosol
Progestrel
Progestron
Progestronol
Progestérone
Projestaject
Prolets
Prolidon
Prolutin
Proluton
Prolutone
Prometrium
Prometrium (TN)
Prontogest
Protormone
S00293
S1705_Selleck
SAM001247039
SMR000058345
SMR000653542
SPBio_002553
SR-01000000088
SR-01000000088-5
Spectrum5_002053
Syngesterone
Syngestrets
Synovex S
Syntolutan
U 3672
UNII-4G7DS2Q64Y
Utrogest
Utrogestan
Vitarrine
WLN: L E5 B666 OV MUTJ A1 E1 FV1
ZINC04428529
beta-Progesterone
bmse000482
component of Cyclogesterin
corpus luteum hormone
delta(4)-Pregnene-3,20-dione
delta(Sup 4)-Pregnene-3,20-dione
delta(Sup4)-pregnene-3,20-dione
delta(sup 4)-Pregnene-3,20-dione
delta4-Pregnene-3,20-dione
luteohormone
nchembio.2007.53-comp14
9
Letrozoleapproved, investigationalPhase 3, Phase 2, Phase 1358112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
10
Medroxyprogesterone Acetateapproved, investigationalPhase 313671-58-9
Synonyms:
(6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione
17-Acetoxy-6alpha-methylprogesterone
17-Acetoxy-6α-methylprogesterone
17alpha-Hydroxy-6alpha-methylprogesterone acetate
17α-hydroxy-6α-methylprogesterone acetate
6-alpha-Methyl-17-alpha-acetoxyprogesterone
6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate
6alpha-Methyl-17-acetoxy progesterone
6alpha-Methyl-17alpha-hydroxyprogesterone acetate
6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetate
6α-Methyl-17-acetoxy progesterone
 
6α-Methyl-17α-hydroxyprogesterone acetate
Depo-provera
Depo-subq Provera
MPA
Makena
Medroxyacetate progesterone
Medroxyprogesterone 17-acetate
Medroxyprogesterone Acetate
Medroxyprogesterone acetate
Methylacetoxyprogesterone
Metigestrona
Provera
11
Trastuzumabapproved, investigationalPhase 3, Phase 2726180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
12
Exemestaneapproved, investigationalPhase 3197107868-30-460198
Synonyms:
(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
107868-30-4
6-Methylenandrosta-1,4-diene-3,17-dione
6-Methyleneandrosta-1,4-diene-3,17-dione
6-methylideneandrosta-1,4-diene-3,17-dione
AC-2171
AC1L1SRB
AC1Q6AAZ
Ambap107868-30-4
Aromasil
Aromasin
Aromasin (TN)
Aromasin, Exemestane
Aromasine
C056516
C08162
CHEBI:4953
CHEMBL1200374
CID60198
CPD000466314
Curator_000009
D00963
DB00990
EXE
EXEMESTANE
 
Exemestance
Exemestane
Exemestane (JAN/USP/INN)
Exemestane [USAN:INN:BAN]
Exemestano
Exemestano [INN-Spanish]
Exemestanum
Exemestanum [INN-Latin]
FCE-24304
Fce 24304
HMS2051J04
HSDB 7463
LS-19329
MLS000759419
MLS001424062
MolPort-003-847-343
NSC713563
Nikidess
PNU-155971
Pfizer brand of exemestane
S1196_Selleck
S1196_Sellek
SAM001246574
SMR000466314
UNII-NY22HMQ4BX
ZINC03973334
exemestane
13
MetforminapprovedPhase 31645657-24-9, 1115-70-414219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMBG
DMGG
Diabefagos
Diabetosan
Diabex
Diaformin
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Meguan
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin Hydrochloride
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
Obimet
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
14
ado-trastuzumab emtansineapprovedPhase 3621018448-65-1
Synonyms:
Kadcyla
 
Trastuzumab-DM1
trastuzumab emtansine
trastuzumab-MCC-DM1
15
PaclitaxelapprovedPhase 3, Phase 2262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
16
Folic Acidapproved, nutraceuticalPhase 3292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
17
Docetaxelapproved, investigational, Approved May 1996Phase 3, Phase 21844114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docefrez
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
18Bone Density Conservation AgentsPhase 3, Phase 2, Phase 12600
19Nucleic Acid Synthesis InhibitorsPhase 33836
20Immunosuppressive AgentsPhase 3, Phase 210422
21Folic Acid AntagonistsPhase 31643
22Topoisomerase InhibitorsPhase 3, Phase 2, Phase 14081
23Immunologic FactorsPhase 3, Phase 2, Phase 118483
24Vitamin B ComplexPhase 32847
25mometasone furoatePhase 314483919-23-7
26Estrogen AntagonistsPhase 3, Phase 2, Phase 11155
27Anti-Inflammatory AgentsPhase 3, Phase 1, Phase 28478
28Aromatase InhibitorsPhase 3, Phase 2, Phase 1721
29Antineoplastic Agents, HormonalPhase 3, Phase 2, Phase 14256
30Dermatologic AgentsPhase 34555
31Raloxifene HydrochloridePhase 364
32Tubulin ModulatorsPhase 3, Phase 24279
33Calcium, DietaryPhase 3, Phase 14678
34
MedroxyprogesteronePhase 3136520-85-410631
Synonyms:
(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
(6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione
17 alpha Hydroxy 6 alpha Methylprogesterone
17 alpha-Hydroxy-6 alpha-Methylprogesterone
17-Hydroxy-6.alpha.-methylprogesterone
17-Hydroxy-6a-methylprogesterone
17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6alpha-methylprogesterone
17.alpha.-Hydroxy-6.alpha.-methylprogesterone
17alpha-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione
17alpha-Hydroxy-6alpha-methylprogesterone
4-08-00-02211 (Beilstein Handbook Reference)
46411_FLUKA
46411_RIEDEL
520-85-4
6-Dihydromegestrol
6-alpha-Methyl-17-alpha-hydroxyprogesterone
6.alpha.-Methyl-17.alpha.-hydroxyprogesterone
6alpha-Methyl-17alpha-hydroxyprogesterone
6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione
6alpha-Methyl-5-pregnen-17alpha-ol-3,20-dione
AC-14528
AC1L1VM7
Adgyn Medro
Aragest
Aragest 5
Asconale
BRN 2510965
C07119
CBP-1011
CHEBI:6715
CHEMBL1390
CID10631
CPD000058769
Clinofem
Clinovir
Colirest
Cycrin
D008525
D08166
DB00603
DMPA
Depo-Clinovir
Depo-Prodasone
Depo-Progestin
Depo-Promone
Depo-Provera
Depo-Subq Provera 104
Depot-Medroxyprogesterone acetate
EINECS 208-298-6
Farlutal
Farlutal inyectable
Farlutal inyectable (TN)
Farlutin
G-Farlutal
Gestapuran
HMS2052A13
HSDB 3114
Hematrol
Hydroxymethylprogesterone
Hysron
 
Indivina
LMST02030176
LS-118713
Lunelle
Lutopolar
Lutoral
M6013_SIGMA
MAP
MLS000069571
MLS001076098
MPA Gyn 5
Med-Pro
Medroprogesterone Acetate
Medrossiprogesterone
Medrossiprogesterone [DCIT]
Medrossiprogesterone [Dcit]
Medroxiprogesterona
Medroxiprogesterona [INN-Spanish]
Medroxiprogesteronum
Medroxyprogesteron
Medroxyprogesteron acetate
Medroxyprogesterone (INN)
Medroxyprogesterone Acetate
Medroxyprogesterone Strakan Brand
Medroxyprogesterone [INN:BAN]
Medroxyprogesteronum
Medroxyprogesteronum [INN-Latin]
Meprate
Methylhydroxyprogesterone
Metigestrona
MolPort-005-934-866
NCGC00023064-04
NSC 27408
NSC27408
Nadigest
Nidaxin
Novo-Medrone
Oragest
Perlutex
Perlutex Leo
Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6-alpha)- (9CI)
Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)- (9CI)
Prodasone
Progestalfa
Progevera
Provera
Proverone
Ralovera
Repromap
Repromix
SAM001246906
SMR000058769
ST082267
Sirprogen
Sodelut G
Strakan Brand of Medroxyprogesterone
U 8840
UNII-HSU1C9YRES
Veramix
ZINC05763835
g-Farlutal
medroxyprogesterone
35Contraceptives, OralPhase 3, Phase 2, Phase 03734
36Selective Estrogen Receptor ModulatorsPhase 3, Phase 2, Phase 1501
37Contraceptive Agents, MalePhase 3202
38Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 2, Phase 1, Phase 09988
39HormonesPhase 3, Phase 2, Phase 1, Phase 011748
40Estrogen Receptor ModulatorsPhase 3, Phase 2, Phase 1544
41EstrogensPhase 3, Phase 2, Phase 12144
42Hormone AntagonistsPhase 3, Phase 2, Phase 1, Phase 010002
43Anti-Allergic AgentsPhase 31312
44Estrogens, Conjugated (USP)Phase 3, Phase 284
45Alkylating AgentsPhase 3, Phase 23582
46Antineoplastic Agents, AlkylatingPhase 3, Phase 23406
47Antirheumatic AgentsPhase 3, Phase 2, Phase 18496
48Contraceptive AgentsPhase 3, Phase 01706
49Antimetabolites, AntineoplasticPhase 3, Phase 25770
50Antimitotic AgentsPhase 3, Phase 24296

Interventional clinical trials:

(show top 50)    (show all 197)
idNameStatusNCT IDPhase
1Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®CompletedNCT01448447Phase 4
2Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast CancerCompletedNCT00742222Phase 4
3Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT SystemRecruitingNCT01644669Phase 4
4Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast CancerCompletedNCT01112254Phase 3
5Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment DecisionsCompletedNCT00262899Phase 3
6Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in SituCompletedNCT00438659Phase 3
7Intraoperative Gamma Camera for Breast Cancer SurgeryCompletedNCT00757302Phase 3
8S9630, Medroxyprogesterone in Treating Women With Breast CancerCompletedNCT00002920Phase 3
9Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast CancerCompletedNCT00026286Phase 3
10Study of Docetaxel in Breast Cancer PatientsCompletedNCT00174707Phase 3
11Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal WomenCompletedNCT00003906Phase 3
12Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in SituRecruitingNCT00907868Phase 3
13Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerRecruitingNCT01272037Phase 3
14Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast CancerRecruitingNCT01905046Phase 3
15Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone LumpectomyActive, not recruitingNCT00769379Phase 3
16Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation TherapyActive, not recruitingNCT00053898Phase 3
17Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the BreastActive, not recruitingNCT00470236Phase 3
18Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in SituActive, not recruitingNCT00003857Phase 3
19Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In SituActive, not recruitingNCT00072462Phase 3
20Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast CancerActive, not recruitingNCT00103181Phase 3
21APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast CancerActive, not recruitingNCT00402519Phase 3
22RAPID: Randomized Trial of Accelerated Partial Breast IrradiationActive, not recruitingNCT00282035Phase 3
23Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by SurgeryActive, not recruitingNCT01349322Phase 3
24Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing CoordinatorActive, not recruitingNCT00321048Phase 3
25Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerActive, not recruitingNCT00878709Phase 3
26A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast CancerActive, not recruitingNCT01358877Phase 3
27A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)Active, not recruitingNCT01772472Phase 3
28A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive PrimaryActive, not recruitingNCT01966471Phase 3
29Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial NeoplasiaActive, not recruitingNCT01357772Phase 3
30Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast CancerActive, not recruitingNCT00004205Phase 3
31Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast CancerActive, not recruitingNCT00083174Phase 3
32Breast Cancer WEight Loss Study (BWEL Study)Not yet recruitingNCT02750826Phase 3
33Management of Low-risk DCISNot yet recruitingNCT02492607Phase 3
34Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCISWithdrawnNCT00324714Phase 3
354-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in SituCompletedNCT00952731Phase 2
36Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast CancerCompletedNCT00416403Phase 2
37Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast CancerCompletedNCT00054301Phase 2
38MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-SituCompletedNCT00586326Phase 2
39Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast CancerCompletedNCT00354640Phase 2
40Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast BiopsyCompletedNCT00843167Phase 2
41Breast Cancer Chemoprevention by SOM230, an IGF-I Action InhibitorCompletedNCT01372618Phase 2
42Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal SymptomsCompletedNCT01194440Phase 2
43Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast CancerCompletedNCT00334542Phase 2
44Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast CancerCompletedNCT00244959Phase 2
45A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.CompletedNCT00545688Phase 2
46Three Different Programs of Paced Breathing in Treating Hot Flashes in WomenCompletedNCT00569166Phase 2
47Letrozole in Preventing Breast Cancer in Postmenopausal WomenCompletedNCT00090857Phase 2
48Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast DiseaseCompletedNCT00031720Phase 2
49Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast CancerCompletedNCT00182793Phase 2
50Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)RecruitingNCT01023477Phase 1, Phase 2

Search NIH Clinical Center for Ductal Carcinoma in Situ

Genetic Tests for Ductal Carcinoma in Situ

About this section

Anatomical Context for Ductal Carcinoma in Situ

About this section

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

33
Breast, Lymph node, Prostate, Bone, Testes, Lung, Skin

Animal Models for Ductal Carcinoma in Situ or affiliated genes

About this section

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

38 (show all 26)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053828.5AR, CCND1, EGFR, ERBB2, KRT14, KRT5
2MP:00011868.0AR, BRCA1, CDKN2A, CYP19A1, EGFR, KRT14
3MP:00053717.8AR, BRCA1, BRCA2, EGFR, ERBB2, ESR1
4MP:00030127.6CDH1, CDKN2A, EGFR, ESR1, ESR2, KRT5
5MP:00053757.6AR, BRCA1, CYP19A1, EGFR, ESR1, ESR2
6MP:00053707.5AR, CDKN2A, CYP19A1, EGFR, ESR1, ESR2
7MP:00053677.4AR, BRCA1, CLDN7, CYP19A1, EGFR, ESR1
8MP:00053887.3BRCA1, CCND1, CDKN2A, EGFR, ERBB2, ESR1
9MP:00053807.1AR, BRCA1, BRCA2, CDH1, CDKN2A, EGFR
10MP:00028736.7AR, BRCA1, BRCA2, CCND1, CDH1, CYP19A1
11MP:00053696.6AR, BRCA1, CDKN2A, CYP19A1, EGFR, ERBB2
12MP:00036316.3AR, BRCA1, BRCA2, CCND1, CDKN2A, CYP19A1
13MP:00053866.1AR, BRCA1, BRCA2, CCND1, CDKN2A, CYP19A1
14MP:00020065.9AR, BRCA1, BRCA2, CCND1, CDH1, CDKN2A
15MP:00053905.8AR, BRCA1, BRCA2, CCND1, CDKN2A, CYP19A1
16MP:00053855.7AR, BRCA1, CCND1, CDH1, CDKN2A, CYP19A1
17MP:00053795.6AR, BRCA1, BRCA2, CCND1, CDH1, CDKN2A
18MP:00053895.5AR, BRCA1, BRCA2, CCND1, CDH1, CDKN2A
19MP:00053845.4AR, BRCA1, BRCA2, CCND1, CDH1, CDKN2A
20MP:00053815.4AR, BRCA1, BRCA2, CCND1, CDH1, CDKN2A
21MP:00053875.2AR, BRCA1, BRCA2, CCND1, CDH1, CDKN2A
22MP:00107684.8AR, BRCA1, BRCA2, CCND1, CDH1, CDKN2A
23MP:00053764.8AR, BRCA1, BRCA2, CCND1, CDH1, CDKN2A
24MP:00053974.8AR, BRCA1, BRCA2, CCND1, CDKN2A, CLDN7
25MP:00107714.8AR, BRCA1, BRCA2, CCND1, CDH1, CDKN2A
26MP:00053784.6AR, BRCA1, BRCA2, CCND1, CDH1, CDKN2A

Publications for Ductal Carcinoma in Situ

About this section

Articles related to Ductal Carcinoma in Situ:

(show top 50)    (show all 781)
idTitleAuthorsYear
1
The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. (27160733)
2016
2
Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). (26542585)
2015
3
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. (26424776)
2015
4
Expression of CD151/Tspan24 and integrin alpha 3 complex in aid of prognostication of HER2-negative high-grade ductal carcinoma in situ. (26464707)
2015
5
A Call for Change in the Diagnosis and Treatment of Patients with Ductal Carcinoma In Situ: An Opportunity to Minimize Overdiagnosis and Overtreatment. (26547899)
2015
6
Histopathological characteristics of breast ductal carcinoma in situ and association with imaging findings. (25644245)
2015
7
Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. (24948027)
2014
8
Post-operative radiotherapy for ductal carcinoma in situ of the breast. (24259251)
2013
9
Hypofractionated radiation therapy for breast ductal carcinoma in situ. (24113057)
2013
10
Patient, tumor and therapeutic features related to recurrence of ductal carcinoma in situ (DCIS). (24322025)
2013
11
Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. (23208501)
2013
12
US appearance of ductal carcinoma in situ. (23322838)
2013
13
Clinicopathologic features of ductal carcinoma in situ in young women with an emphasis on molecular subtype. (24029706)
2013
14
Factors influencing the quality of local management of ductal carcinoma in situ: a cohort study. (23737691)
2013
15
Molecular phenotypes of ductal carcinoma-in-situ and invasive ductal carcinoma: a comparative study. (22499299)
2012
16
Neuroendocrine ductal carcinoma in situ, comedo type, of the breast detected by screening mammography: a potentially pre-invasive counterpart of high grade neuroendocrine tumours. (22437750)
2012
17
Multi-institutional experience of ductal carcinoma in situ in black vs white patients treated with breast-conserving surgery and whole breast radiation therapy. (22672752)
2012
18
Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases. (22795363)
2012
19
Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. (22134623)
2012
20
ACR appropriateness criteria(Ar) ductal carcinoma in situ. (22107336)
2012
21
Cell polarity, epithelial-mesenchymal transition, and cell-fate decision gene expression in ductal carcinoma in situ. (22577534)
2012
22
Breast cancer and ductal carcinoma in situ among women with prior squamous or glandular precancer in the cervix: a register-based study. (23011481)
2012
23
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. (21145284)
2011
24
Development and pilot testing of a communication aid to assist clinicians to communicate with women diagnosed with ductal carcinoma in situ (DCIS). (21088858)
2011
25
Intraoperative assessment of surgical margins during breast conserving surgery of ductal carcinoma in situ by use of radiofrequency spectroscopy. (21885281)
2011
26
Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast. (20701550)
2011
27
Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. (21493791)
2011
28
Mammographycally occult high grade ductal carcinoma in situ (DCIS) as second primary breast cancer, detected with MRI: a case report. (22933920)
2010
29
Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast. (20704578)
2010
30
Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. (21060026)
2010
31
Ductal carcinoma in situ: terminology, classification, and natural history. (20956817)
2010
32
Coronal serial sequential sampling of breast specimen in the assessment of the extent of ductal carcinoma in situ. (19722734)
2009
33
P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma. (19190693)
2007
34
Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. (16807982)
2006
35
Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? (15832086)
2005
36
Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ. (15827818)
2005
37
S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast. (15217497)
2004
38
p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2. (15318938)
2004
39
Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. (14717665)
2004
40
Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast. (12147647)
2002
41
Immunohistochemical expression of uPA, PAI-1, cathepsin D and apoptotic cells in ductal carcinoma in situ of the breast. (12016391)
2002
42
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. (11912139)
2002
43
Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. (12434415)
2002
44
p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. (11333292)
2001
45
Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. (11381366)
2001
46
Atypical cystic lobule of the breast: an early stage of low-grade ductal carcinoma in-situ. (11114859)
2000
47
Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. (9212742)
1997
48
Controversies in the treatment of ductal carcinoma in situ. (8610262)
1996
49
50

Variations for Ductal Carcinoma in Situ

About this section

Cosmic variations for Ductal Carcinoma in Situ:

7 (show all 30)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM516KRASbreast,NS,carcinoma in situ,ductal carcinoma in situ7
2COSM520KRASbreast,NS,carcinoma in situ,ductal carcinoma in situ7
3COSM521KRASbreast,NS,carcinoma in situ,ductal carcinoma in situ7
4COSM532KRASbreast,NS,carcinoma in situ,ductal carcinoma in situ7
5COSM565NRASbreast,NS,carcinoma in situ,ductal carcinoma in situ7
6COSM580NRASbreast,NS,carcinoma in situ,ductal carcinoma in situ7
7COSM754PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ7
8COSM760PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ7
9COSM763PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ7
10COSM775PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ7
11COSM776PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ7
12COSM6932TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
13COSM10656TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
14COSM10660TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
15COSM10662TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
16COSM10701TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
17COSM10779TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
18COSM10867TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
19COSM11089TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
20COSM12458PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ7
21COSM14060ERBB2breast,NS,carcinoma in situ,ductal carcinoma in situ7
22COSM33765AKT1breast,NS,carcinoma in situ,ductal carcinoma in situ7
23COSM43559TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
24COSM43714TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
25COSM43814TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
26COSM44415TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
27COSM44901TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7
28COSM19786CDH1breast,NS,carcinoma in situ,ductal carcinoma in situ7
29COSM774PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ7
30COSM44737TP53breast,NS,carcinoma in situ,ductal carcinoma in situ7

Expression for genes affiliated with Ductal Carcinoma in Situ

About this section
Search GEO for disease gene expression data for Ductal Carcinoma in Situ.

Pathways for genes affiliated with Ductal Carcinoma in Situ

About this section

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50)    (show all 51)
idSuper pathwaysScoreTop Affiliating Genes
19.8EGFR, ERBB2, TP53
2
Show member pathways
9.7CCND1, EGFR, ESR1
39.7CCND1, EGFR, ESR1
49.7CDH1, EGFR, ERBB2
59.7CDH1, EGFR, ERBB2
69.7BRCA1, CCND1, ERBB2
79.7BRCA1, BRCA2, TP53
89.7BRCA1, CCND1, TP53
99.7BRCA1, CCND1, TP53
109.7BRCA2, CCND1, ESR1
119.6KRT14, KRT5, TP53
129.6CCND1, CDH1, TP53
139.6ESR1, PTGS2, TP53
149.5CCND1, PTGS2, TP53
15
Show member pathways
9.5CCND1, EGFR, ERBB2, TP53
16
Show member pathways
9.5CCND1, EGFR, ERBB2, TP53
179.4CCND1, ESR1, ESR2
189.4CYP19A1, ESR2, PGR
19
Show member pathways
9.4AR, BRCA1, ESR1
209.4CYP19A1, ESR1, ESR2
219.3AR, BRCA1, CCND1
229.3CCND1, EGFR, ERBB2, ESR1, TP53
23
Show member pathways
9.3CDH1, EGFR, ERBB2, MUC1
249.2AR, CCND1, CDH1
259.2CCND1, CDH1, PTGS2, TP53
26
Show member pathways
9.2CCND1, CDH1, EGFR, ERBB2, TP53
27
Show member pathways
9.1AR, CCND1, EGFR, ERBB2
289.1AR, CCND1, ESR1, TP53
29
Show member pathways
9.1CDH1, ERBB2, ESR1, PTGS2, TP53
30
Show member pathways
9.1AR, BRCA1, CCND1, TP53
319.0AR, BRCA1, CCND1, EGFR
329.0CDH1, EGFR, ERBB2, MUC1, TP53
339.0CCND1, CDH1, EGFR, PTGS2, TP53
34
Show member pathways
8.9CCND1, CDKN2A, ERBB2, TP53
35
Show member pathways
8.9AR, ESR1, ESR2, PGR
368.9CCND1, CDKN2A, EGFR, TP53
37
Show member pathways
8.9BRCA1, CCND1, CDKN2A, TP53
388.8CCND1, CDH1, CDKN2A, TP53
39
Show member pathways
8.7BRCA1, CCND1, CDKN2A, ESR1, PGR
40
Show member pathways
8.7BRCA1, BRCA2, CCND1, ESR1, ESR2, TP53
41
Show member pathways
8.6CCND1, EGFR, ERBB2, ESR1, ESR2, PTGS2
42
Show member pathways
8.4BRCA2, CCND1, CDKN2A, EGFR, ERBB2, TP53
438.4CCND1, CDH1, CDKN2A, EGFR, ERBB2, TP53
448.0BRCA1, CCND1, CDKN2A, EGFR, ERBB2, PTGS2
457.6AR, BRCA1, BRCA2, CCND1, CDH1, CYP19A1
46
Show member pathways
7.2AR, BRCA1, BRCA2, CCND1, CDH1, CDKN2A
477.2AR, BRCA1, BRCA2, CCND1, EGFR, ERBB2
487.0AR, BRCA2, CCND1, CDH1, CDKN2A, EGFR
49
Show member pathways
7.0BRCA1, BRCA2, CCND1, CDKN2A, EGFR, ERBB2
50
Show member pathways
6.5BRCA1, CCND1, CDH1, CDKN2A, EGFR, ERBB2

GO Terms for genes affiliated with Ductal Carcinoma in Situ

About this section

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1hemidesmosome assemblyGO:003158110.5KRT14, KRT5
2Sertoli cell developmentGO:006000910.4ESR1, ESR2
3Sertoli cell proliferationGO:006001110.4ESR1, ESR2
4regulation of neuron apoptotic processGO:004352310.4ESR1, ESR2
5chordate embryonic developmentGO:004300910.3BRCA1, BRCA2
6Leydig cell differentiationGO:003332710.0AR, CCND1
7mammary gland alveolus developmentGO:006074910.0AR, CCND1
8prostate gland developmentGO:00308509.8AR, ESR2
9DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:00069789.6BRCA1, BRCA2, MUC1, TP53
10replicative senescenceGO:00903999.5CDKN2A, TP53
11protein sumoylationGO:00169259.5BRCA1, CDKN2A, TP53
12cellular response to DNA damage stimulusGO:00069749.4BRCA1, BRCA2, CCND1, TP53
13gene expressionGO:00104679.3AR, ESR1, PGR, TP53
14transcription initiation from RNA polymerase II promoterGO:00063679.1AR, ESR1, ESR2, PGR
15negative regulation of cell growthGO:00303089.1CDKN2A, ESR2, TP53
16response to estradiolGO:00323558.9BRCA2, CCND1, ESR2, PTGS2
17positive regulation of transcription, DNA-templatedGO:00458937.8AR, BRCA2, CDH1, CDKN2A, ESR1, ESR2
18positive regulation of transcription from RNA polymerase II promoterGO:00459447.6AR, BRCA1, CDKN2A, EGFR, ESR1, ESR2

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1receptor signaling protein tyrosine kinase activityGO:00047169.9EGFR, ERBB2
2core promoter sequence-specific DNA bindingGO:00010469.7ESR1, ESR2

Sources for Ductal Carcinoma in Situ

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet